Related Experiment Video
Updated: Mar 6, 2026

07:30
Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
Published on: June 15, 2019
10.7K
Recent advances in ROS-modulating materials for sepsis treatment
Xin Wang Mo1, Dong Kwang Min1, Jaeyun Kim2
1School of Chemical Engineering, Sungkyunkwan University (SKKU), Suwon 16419, Republic of Korea.
Summary
Reactive oxygen species (ROS) play a dual role in sepsis. This review explores ROS-modulating materials and therapies, including ROS-generating and scavenging systems, for improved sepsis treatment.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Immunology
- Biochemistry
Background:
- Sepsis involves uncontrolled immune responses and dysregulated reactive oxygen species (ROS) levels.
- While moderate ROS are crucial for immune function, excessive ROS cause oxidative damage and organ failure.
- Nanomaterials offer novel strategies to modulate ROS dynamics for sepsis management.
Purpose of the Study:
- To review recent advancements in ROS-modulating materials for sepsis treatment.
- To discuss ROS-generating and ROS-scavenging systems, including extracorporeal hemoperfusion.
- To analyze their mechanisms, targeting, therapeutic potential, and translational challenges.
Main Methods:
- Literature review of ROS-modulating materials and therapies in sepsis.
- Analysis of ROS-generating nanomaterials (nanozymes, photosensitizers, sonosensitizers).
- Evaluation of ROS-scavenging materials (enzymes, nanozymes, polyphenols) and hemoperfusion.
Main Results:
- ROS-generating materials precisely eliminate pathogens and combat antibiotic resistance.
- ROS-scavenging materials restore redox balance and protect tissues from oxidative stress.
- Extracorporeal hemoperfusion offers continuous ROS removal from the bloodstream.
Conclusions:
- ROS-modulating materials present a promising therapeutic avenue for sepsis.
- Balancing ROS generation and scavenging is key to effective sepsis treatment.
- Further research is needed to address biocompatibility and translational challenges for clinical application.

